慢性阻塞性肺疾病结局的蛋白质生物标志物
本文综述了与慢阻肺临床相关结局(如FEV1、FEV1下降、CT肺气肿测量、急性加重频率)相关的蛋白质生物标志物证据。α1-抗胰蛋白酶是原型标志物但仅占慢阻肺的1%至5%;纤维蛋白原、晚期糖基化终产物可溶性受体、表面活性蛋白D、俱乐部细胞分泌蛋白等新型标志物不断涌现,但单一标志物仅能解释部分风险增加,需多标志物组合才能全面解释个体和人群的临床变异与风险。
要点
- α1-抗胰蛋白酶是原型慢阻肺蛋白标志物,但仅解释1%至5%的慢阻肺。
- 纤维蛋白原、sRAGE、SP-D、CCSP等新型标志物与慢阻肺结局相关。
- 单一标志物仅解释部分风险增加,多标志物组合才能全面解释临床变异。
核心结论
- 多种蛋白质生物标志物与慢阻肺临床相关结局相关,但单一标志物仅解释部分风险增加,需多标志物组合才能全面解释个体和人群的临床变异与风险。
研究设计与样本
- 综述,聚焦与慢阻肺临床相关结局相关的蛋白质生物标志物,总结已验证标志物的证据并讨论其优势、不足及转化所需的监管步骤。
主要发现
- α1-抗胰蛋白酶是原型慢阻肺蛋白标志物,但仅占慢阻肺的1%至5%。
- 纤维蛋白原、晚期糖基化终产物可溶性受体、表面活性蛋白D、俱乐部细胞分泌蛋白等新型标志物不断涌现。
- 个体生物标志物仅解释部分慢阻肺风险增加,需多标志物面板才能全面解释临床变异和风险。
临床怎么用
- 临床可关注已验证的蛋白质标志物(如纤维蛋白原、sRAGE、SP-D、CCSP)与慢阻肺结局的关联,但需认识单一标志物的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
COPD is a clinically heterogeneous syndrome characterized by injury to airways, airspaces, and lung vasculature and usually caused by tobacco smoke and/or air pollution exposure. COPD is also independently associated with nonpulmonary comorbidities (eg, cardiovascular disease) and malignancies (eg, GI, bladder), suggesting a role for systemic injury. Since not all those with exposure develop COPD, there has been a search for plasma and lung biomarkers that confer increased cross-sectional and longitudinal risk. This search typically focuses on clinically relevant COPD outcomes such as FEV1, FEV1 decline, CT measurements of emphysema, or exacerbation frequency. The rapid advances in omics technology and the molecular phenotyping of COPD cohorts now permit large-scale evaluation of genetic, transcriptomic, proteomic, and metabolic biomarkers. This review focuses on protein biomarkers associated with clinically relevant COPD outcomes. The prototypic COPD protein biomarker is alpha-1 antitrypsin; however, this biomarker only accounts for 1% to 5% of COPD. This article reviews and summarizes the evidence for other validated biomarkers for each COPD outcome, and discusses their advantages, weaknesses, and required regulatory steps to move the biomarker from the bench into clinic. Although we highlight the emergence of many novel biomarkers (eg, fibrinogen, soluble receptor for advanced glycation, surfactant protein D, club cell secretory protein), there is increasing evidence that individual biomarkers only explain a fraction of the increased COPD risk and that multiple biomarker panels are needed to completely explain clinical variation and risk in individuals and populations.
引用
- Serban KA, Pratte KA, Bowler RP, et al. Protein Biomarkers for COPD Outcomes. Chest. 2021. PMID: 33434499. doi:10.1016/j.chest.2021.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。